Cipla
Cipla posted record India sales of ₹3,452 crore in the June quarter (The Hindu BusinessLine, 23 Jul), with Yurpeak sales at ₹28 crore in June (ET Small Business, 23 Jul), but consolidated net profit fell 39.2% to ₹789.05 crore (Financial Express, 23 Jul) and Maharashtra FDA cancelled licences at its Pune warehouse on October 1 (ET Small Business, 2 Oct). Rival generic makers face a Cipla pushing tirzepatide through non-metro distribution while it holds ₹10,094 crore in cash (The Hindu BusinessLine).
Latest moves
Our read of each move first, where we have one; what the report said is marked Reported.
Background
From 5 stories, the newest dated 2 Oct 2026. Summary written 2 Oct 2026.
Cipla is an Indian pharmaceutical company and drugmaker. [1] source: Business Standard[2] source: The Hindu BusinessLine
Show 2 more paragraphs and 5 sources
In September 2026, Cipla was identified among Indian drugmakers expanding into consumer wellness and nutraceuticals as GLP-1 weight-loss therapies created demand for supplements; the same account said Cipla had acquired 100% of Inzpera Healthsciences. [2] source: The Hindu BusinessLine
A deal described in September 2026 as having first been agreed in April 2024 saw Cipla Health agree to acquire Ivia Beaute’s cosmetics and personal-care distribution and marketing business for Rs 130 crore at closing, with Rs 110 crore contingent on milestones over the next 3 years; the deal included Astaberry, Ikin and Bhimsaini worldwide. [3] source: Business Standard On October 1, 2026, Maharashtra FDA cancelled Cipla Pharma & Life Sciences Ltd’s Pune warehouse sale and distribution licences over Reactin Plus packaging claims and deficiencies in storage, expired-medicine handling, documentation and inventory management. [4] source: ET Small Business In August 2026, Cipla was contesting an earlier cancellation of its Pune warehouse drug-sale licence and said no product safety, quality or patient-safety issue was alleged. [5] source: The Hindu BusinessLine
Sources
Stories that mention Cipla
3 stories
Cipla is named in these stories but is not their subject.